Daniel Shao-Weng Tan

机构：Duke-NUS Medical School, National Cancer Centre Singapore · ORCID：0009-0005-4021-2176

发表论文 304 篇 · 总被引 9660 次 · h-index 44

代表论文

• Sevabertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer (2025 · New England Journal of Medicine · 被引 62)
• Prediction of Small-Molecule Partitioning into Biomolecular Condensates from Simulation (2025 · JACS Au · 被引 18)
• TROPION-Lung12: A phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non–small cell lung cancer (2025 · Journal of Thoracic and Cardiovascular Surgery · 被引 8)
• 925MO First-in-human phase I/Ib study of the oral Werner (WRN) helicase inhibitor HRO761 in patients (pts) with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced solid tumors: Interim safety and efficacy analysis from HRO761 single agent dose escalation (2025 · Annals of Oncology · 被引 6)
• Activity of Brigatinib in Patients With Crizotinib-Resistant ALK-positive Non–Small-Cell Lung Cancer According to ALK Fusion and Mutation Status (2025 · Clinical Lung Cancer · 被引 2)
• Efficacy and safety of larotrectinib in patients with TRK fusion lung cancer: An updated analysis. (2025 · Journal of Clinical Oncology · 被引 2)